Asthma chronic obstructive pulmonary disease

Patients with lung cancer frequently have numerous concurrent medical problems. Such problems may be related to invasion of the primary tumor and its metastases, paraneoplastic syndromes (see clinical presentation, above), chemotherapy and radiotherapy toxicity, or concomitant disease states (e.g., cardiac disease, renal dysfunction, chronic obstructive pulmonary disease, asthma, or diabetes). Depression is also common and sometimes persistent in patients with SCLC and NSCLC and should be treated. Identification, diagnosis, and treatment of the patient as a whole may improve the patient s overall quality of life and tolerance to cancer treatments. 

Johnson M (2004) Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 1 200-6... 

Monitor for adverse effects of 3-blockers—heart rate, blood pressure, fatigue, masking of symptoms of hypoglycemia and/or glucose intolerance (in patients with diabetes), wheezing or shortness of breath (in patients with asthma or chronic obstructive pulmonary disease), etc. 

Stemmier S, Arinir U, Klein W, et al. Association of interleukin-8 receptor alpha polymorphisms with chronic obstructive pulmonary disease and asthma. Genes Immun 2005 6(3) 225-230. 

Atenolol, betaxolol, bisoprolol, and metoprolol are cardioselective at low doses and bind more avidly to /Ij-receptors than to /J2-receptors. As a result, they are less likely to provoke bronchospasm and vasoconstriction and may be safer than nonselective /1-blockers in patients with asthma, chronic obstructive pulmonary disease, diabetes, and PAD. Cardioselectiv-ity is a dose-dependent phenomenon, and the effect is lost at higher doses. 

Asthma, chronic obstructive pulmonary disease, pulmonary embolism, pneumonia Others... 

The symptoms of many chronic diseases, such as rheumatoid arthritis, multiple sclerosis, asthma and chronic obstructive pulmonary disease (COPD) are caused in large part by an excessive and chronic inflammatory response and are therefore potential human diseases for drugs which inhibit the SSAO/VAP-1 activity. Notably, it has been recently shown that patients suffering from either atopic eczema or psoriasis, both chronic inflammatory skin disorders, demonstrate an increase in SSAO/VAP-1 positive vessels in their skin compared to skin from healthy controls [47,48]. 

Aerosolised medicines have been used for centuries to treat respiratory diseases, with inhalation therapy for the airways focused primarily on the treatment of asthma and chronic obstructive pulmonary disease (COPD). The development of new products for delivery to the lungs for these respiratory diseases includes new steroids and beta agonists plus combination products featuring both agents. New classes of anti-asthma medication are also being developed for inhalation with the aim of delivering them directly to the inflamed airways. 

Aging (skin and other tissues), myocardial infarct or stroke, inflammation, rheumatoid arthritis, atherosclerosis, pulmonary disorders (asthma and chronic obstructive pulmonary diseases), radiation injury, organ transplant rejection, psoriasis, hypertension, AIDS, multiple types of cancer, neuro-degenerative diseases (Parkinson s), diabetes, muscular dystrophy... 

---